Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Washington Drug Letter > Sponsors Want Clarity in Guidance on Gauging Suicidal Thoughts, Behaviors

Washington Drug Letter

Oct. 29, 2012 | Vol. 44 No. 43

Sponsors Want Clarity in Guidance on Gauging Suicidal Thoughts, Behaviors

Amgen and Novartis want the FDA to clarify which compounds would require an assessment of suicidal thoughts and behaviors under draft guidance the agency issued in August.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

FDA Brings HIV-1 Drug Development Guidance Into “Treatment-Experienced” Era The Buzz FDA Issues Guidance on Photostability Evaluations of New Drugs EMA to Update Pediatric AHF Drug Development Guideline

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.